Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

Video

In Partnership With:

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the management of cytokine release syndrome (CRS) in patients with hematologic malignancies who are treated with CAR T-cell therapy.

CRS, or cytokine storm, is caused by a high activation level of immune effector cells that are mediated by cytokines, such as interleukin-6 (IL-6), Hill says. Typically, CRS occurs within the first 2 to 4 days following administration of CAR T-cell therapy.

The cytokines induce a sepsis-like physiological response that may include fever, tachycardia, hypoxia, or hypotension, says Hill. Moreover, these adverse effects typically require the patient to be treated in the intensive care unit.

Management strategies for CRS include the administration of tocilizumab (Actemra), which is an anti­­–IL-6 monoclonal antibody, Hill explains.

However, treatment should take place at an expert-level facility that is experienced in managing CRS, concludes Hill.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD